HIV/STD Laboratory CORE DESCRIPTION
The HIV/STD Laboratory Core of the UNC CFAR offers services and collaborations to HIV researchers for their basic and clinical research projects. The Core provides a GCLP environment for specimen processing and testing.
The HIV/STD Laboratory Core consults and collaborates with researchers at UNC-CH, RTI International, and FHI 360 (as well as outside researchers). Our contributions to recent research projects include:
- developing flow cytometry assays and cytokine ELISA and multiplex bead array panels
- providing instrumentation, e.g. ELISPOT reader
- sequencing of HIV from patients
- testing new microbiologic diagnostic assays on a variety of specimen types
- testing compounds for anti-HIV activity
- measuring prostate specific antigen (PSA) as a marker of sexual activity
- training of personnel in virus work and various assays
The Core serves as a repository for long- and short-term storage of biological specimens from HIV+ patients in the UNC CFAR HIV Clinical Cohort (UCHCC) and maintains a current CDC-USPHS permit for importing HIV+ specimens from foreign countries.
Researchers and clinicians can request services using the button at the top of the page and you can contact us by our email address.
HIV/STD Laboratory CORE NEWS
The HIV/STD Laboratory Core is located on the 5th floor of Taylor Hall, which is adjacent to MBRB. The Basic Science part of the Core lab is in 22-059 Lineberger Cancer Center.
Kristina De Paris, Ph.D.
Core Director
Dr. De Paris is a Professor in the Department of Microbiology and Immunology. The research in the De Paris lab is centered around HIV. The lab is pursuing HIV prevention studies with the goal to understand the determinants that drive the development of broadly neutralizing antibodies against HIV by vaccination. A second area of HIV research is focused on HIV in pregnancy to define biological mechanisms that are associated with higher risk of adverse birth outcomes in women with HIV.
Closely linked to this area of research is an interest in the link between infant immune development and increased susceptibility to infectious diseases in healthy infants and/or infants born to mothers with HIV.
The University of North Carolina at Chapel Hill
Chapel Hill, NC
abelk@med.unc.edu
Office phone: 919-843-9560
Robert Krysiak, MSc
Associate Core Director
Robert Krysiak is a Research Associate at the Institute of Global Health and Infectious Diseases. Rob earned his Master of Science in Microbiology from Thomas Jefferson University and has worked at UNC since 1997. He is a clinical microbiologist and a recognized expert in building and maintaining laboratory systems in resource-limited settings. He has developed an extensive background in international laboratory development and management in nearly fifteen countries in support of public health research targeting infectious diseases, particularly in Sub-Saharan Africa. He was most recently the Laboratory Director at UNC Project-Malawi before joining the HSL Core.
The University of North Carolina at Chapel Hill
Chapel Hill, NC
robert_krysiak@med.unc.edu
John Schmitz, Ph.D.
Clinical Consultant
Dr. Schmitz is a Professor of Pathology and Laboratory Medicine and Microbiology/Immunology and directs the Histocompatibility, Flow Cytometry and Clincal Immunology Laboratories at UNC Hospitals. Dr. Schmitz has experiences in the use of cytokine assays, flow cytometry including cell surface and intracellular cytokine assays as well as lymphocyte proliferation assays. He has used that experience in validating and implementing assays for HIV related research for over 15 years. Prior to establishing the Immunology Core Dr. Schmitz served for 8 years as the Director of the UNC Immunology Support Laboratory, one of 8 Immunology Cores within the ACTG. In addition to his experience providing support of basic, translational and clinical studies of HIV infection, Dr. Schmitz has extensive experience in diagnostic Immunology as director of the Clinical Immunology, Flow Cytometry and Histocompatibility Laboratories at UNC Hospitals. Dr. Schmitz’ 25 years of clinical research experience include assessment of antigen-specific humoral and cell-mediated immune responses, quantitation of soluble markers, immunogenetic testing and molecular diagnostics of infectious diseases.
The University of North Carolina at Chapel Hill
CB# 7600
Chapel Hill, NC
jschmitz@unch.unc.edu
Fax: 919-966-0486
Office Phone: 919-966-8453
Kiera Williams
Research Technician
Laura Langer
Research Technician
Ryan Hansen
Research Specialist
Aidyn Cada
Research Technician
UPDATED November 2019
RIGOR AND REPRODUCIBILITY FOR CFAR HIV/STD LABORATORY CORE
Eight steps to Rigorous and Reproducible Experiments in Biomolecular Research at UNC:
- If using a core facility, consult with the core staff in the planning stage. Consult with a statistician if you need help developing a Power Analysis to assure that your results will be adequately powered.
- Design your experiment with sufficient controls (rigor) and replicates (reproducibility).
- Assure that ALL of your reagents (antibodies, cell lines, mice) are fully validated (see below).
- Have a clear and detailed protocol (SOP) and data analysis plan. Assure that the protocol is strictly followed or that any deviation is well documented.
- Assure that the staff or students performing the experiment are well trained and understand each step and the importance of performing them precisely.
- Use only well-maintained instrumentation, preferably maintained and operated in a core facility with expert staff (see #1 above).
- Document all steps, reagents, equipment and data analysis methods used in the experiment. Assure that the both the documentation and the data itself are properly stored in a safe data management repository.
- Acknowledge the Cancer Center Support Grant (P30 CA016086) (if applicable), other grants that support the core, the core (by name), and core staff in publications.
Guide to Rigor and Reproducibility for the CFAR HIV/STD Laboratory Core
- Consult with the core staff in the planning stage. – Contact Julie Nelson, Core Director at jnelson@med.unc.edu or 919-966-6872
- Depending on the type of testing needed, appropriate controls and standards will be included. Replicates are important and can vary depending on the type of testing and power calculations. Flow cytometry, soluble marker quantitation, HIV quantitation, PSA detection, and HIV inhibition assays all have different controls and standards. Talk to us about the appropriate controls, standards, and replicates for your project.
- Validation of methods must be done when using a kit for a different sample type than the kit was designed for (soluble markers, etc.). The Core has validated methods for HIV quantitation from dried blood spots and PSA detection from vaginal swabs, for instance.
- The HIV/STD Laboratory Core provides training to ensure that all investigators are properly training in our technology unless we are contracted to do the work within the core. Training is provided includes BSL2+ work with HIV or human blood, MagPix and ELISA quantitation, ELISPOT reader use, flow on HIV-infected cells, and in vitro work with HIV. Contact us for more information.
- The CFAR HIV/STD Laboratory Core participates in external quality assurance for PBMC processing through the IQA and is CAP/CLIA accredited. The Core is also GCLP compliant in accordance with NIH DAIDS Network oversight.
- All equipment in the HIV/STD Laboratory Core is maintained per GCLP, CAP, or manufacturer’s instructions. In addition, QC measures are in place per GCLP and CAP.
- Detailed descriptions of experimental procedures and validations, including sample storage and processing, are documented electronically and in notebooks within the Core.
- Please acknowledge the UNC Center for AIDS Research HIV/STD Laboratory Core in your publications. Instructions for acknowledgment can be found here: https://unccfar.org/acknowledge-the-cfar/
UPDATED JUNE 2023
Services | UNC ($) | Non-UNC ($) |
---|---|---|
Abbott VL | 172 | 268 |
T cell T mag | 141 | 220 |
ELISPOT outside CFAR | 60 | 94 |
MagPix/LX200 | 86 | 134 |
Serum with additives | 64 | 100 |
PBMC to 50ml blood CRS | 160 | 249 |
1 spin CRS | 55 | 85 |
2 spin CRS | 55 | 86 |
Aliquots CRS | 55 | 85 |
DBS (supplies only) | 5 | 8 |
Leukopak (handling only) | 225 | 361 |
HLA test from Histogenetics | 195 | 303 |
HLA DNA extraction | 20 | 31 |
Phlebotomy | 60 | 94 |
Donor recruitment | 20 | 31 |
Specimen handling | 35 | 54 |
Dry ice shipping | 118 | 183 |
LN2 shipping | 180 | 279 |
Storage in -20 or -80 freezer; per box per month | 1 | 2 |
Storage in liquid nitrogen freezer; per box per month | 2 | 4 |
Assay labor | 60 | 93 |
Analysis | 100 | 156 |
Consultation | 110 | 172 |
*Cost will be determined for each project to include kits, supplies, and labor
All projects with non-UNC funds will have an additional 55.5% fee
PUBLICATIONS
Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD,
Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC
inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017 Aug 1;127(8):3126–3135.
PMID: 28714868. PMCID: PMC5531421
Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, Jacobson DL, Van Dyke RB,
Geffner ME, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
P219/219C Study, and the Pediatric HIV/AIDS Cohort Study (PHACS). Delay in sexual
maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS Lond Engl. 2017
Jun 1;31(9):1333–1341. PMID: 28358737. PMCID: PMC5472204
Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as
Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847
Chen J, Akhtari FS, Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, Dumond JB.
Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How
Does This Influence the Effect of Aging? Clin Transl Sci. 2018 Mar;11(2):226–236. PMID:
29205871. PMC5866997.
Cheng L, Yu H, Li G, Li F, Ma J, Li J, Chi L, Zhang L, Su L. Type I interferons suppress viral
replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI
Insight. 2017 Jun 15;2(12). PMID: 28614789. PMCID: PMC5470878
Cho H, Mbai I, Luseno WK, Hobbs M, Halpern C, Hallfors DD. School Support as Structural HIV
Prevention for Adolescent Orphans in Western Kenya. J Adolesc Health Off Publ Soc Adolesc
Med. 2018 Jan;62(1):44–51. PMID: 29107569. PMCID: PMC5742035
Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M,
Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K. Increasing JAK/STAT Signaling Function
of Infant CD4(+) T Cells during the First Year of Life. Front Pediatr. 2017;5:15. PMID: 28271056.
PMCID: PMC5318443
Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S,
Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team. Rilpivirine Plasma and Cervico-
Vaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic
Syndr. 2018 Mar 8; PMID: 29528944
Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-
Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C,
Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT,
Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team.
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal
Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-
1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-
Label, Clinical Trial. J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383–392. PMID: 29239901.
PMC5825265.
Gallo MF, Legardy-Williams J, Steiner MJ, Macaluso M, Carter M, Hobbs MM, Hylton-Kong T,
Anderson C, Costenbader E, Warner L. Sexual Relationship Power and Semen Exposure
Among Female Patients at a Sexually Transmitted Infection Clinic in Kingston, Jamaica. Arch
Sex Behav. 2017 Oct;46(7):2157–2164. PMID: 27305908. PMCID: PMC5500443
Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron
JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK, A5321 Team.
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV
Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis. 2018 Feb 26;
PMID: 29529230
Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD,
McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis
DM. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res Hum Retroviruses. 2018 Jan;34(1):111–122. PMID: 28636433.
PMC5771540
Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM,
Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, AIDS Clinical Trials
5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected
Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–1733.
PMID: 28431010. PMCID: PMC5790148
Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ,
Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody
Response Associates with Enhanced Transmission and Infant Morbidity. mBio. 2017 Oct
24;8(5). PMID: 29066544. PMCID: PMC5654929
Hampel D, Shahab-Ferdows S, Gertz E, Flax VL, Adair LS, Bentley ME, Jamieson DJ, Tegha
G, Chasela CS, Kamwendo D, van der Horst CM, Allen LH. The effects of a lipid-based nutrient
supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in
milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers.
Matern Child Nutr. 2018 Apr;14(2):e12503. PMID: 28851037. PMCID: PMC5832511
Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, Kaunda-
Khangamwa B, Compliment K, Stanley C, Cataldo F, van Lettow M, Rosenberg NE, Tweya H,
Gugsa S, Sampathkumar V, Schouten E, Eliya M, Chimbwandira F, Chiwaula L, Kapito-Tembo
A, Phiri S, PURE Malawi Consortium. Viral Suppression and HIV Drug Resistance at 6 Months
Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. J Acquir
Immune Defic Syndr 1999. 2017 Jun 1;75 Suppl 2:S149–S155. PMID: 28498184. PMCID:
PMC5431274
Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M,
McFarland EJ, Van Dyke RB, Jacobson D, Pediatric HIV/AIDS Cohort Study (PHACS)
Adolescent Master Protocol (AMP) study. Improvement in lipids after switch to boosted
atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease
inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 Mar;19(3):175–183.
PMID: 29159965. PMCID: PMC5821593
Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez
AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm
Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected
Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT
P1025 Protocol. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Sep 15;65(6):982–989. PMID:
28575201. PMCID: PMC5849107
Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E,
Chakhtoura N, Burchett S, Mirochnick M, IMPAACT P1026s Protocol Team. Dolutegravir
pharmacokinetics in pregnant and postpartum women living with HIV. AIDS Lond Engl. 2018 Mar
27;32(6):729–737. PMID: 29369162. PMCID: PMC5854536
Patel S, Lam S, Sung J, Cruz R, Goonetilleke N, Xu Y, Kuruc J, Gay C, Jones B, Shpall E,
Margolis D, Ambinder R, Bollard C. HIV specific T cells generated from HIV naive adult
and cord blood donors target a range of novel viral epitopes – implications for a cure
strategy after allogeneic HSCT and CBT. Cytotherapy. 2017;19:S41-2. (poster abstract)
Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B,
Siberry GK, Mirochnick M, IMPAACT P1083 Team. A Phase II/III Trial of Lopinavir/Ritonavir
Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J.
2018 Feb;37(2):e29–e35. PMID: 29088027. PMCID: PMC5762400
Scheidell J, Beau De Rochars V, Séraphin M, Hobbs M, Morris J, Célestin J, Cottier L, Khan M.
Socioeconomic Vulnerability and Sexually Transmitted Infection among Pregnant Haitian
Women. Sex Transm Dis. 2018;Sep;45(9):626-631. PMID: 29697553 PMCID: PMC6086731.
Seña AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, Cook RL, Hobbs MM.
A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among
young, asymptomatic high-risk women in the United States. Clin Infect Dis Off Publ Infect Dis
Soc Am. 2018 Jan 12; PMID: 29342269
Smith JS, Des Marais AC, Deal AM, Richman AR, Perez-Heydrich C, Yen-Lieberman B, Barclay
L, Belinson J, Rinas A, Brewer NT. Mailed Human Papillomavirus Self-Collection With
Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm
Dis. 2018 Jan;45(1):42–48. PMID: 28876298. PMCID: PMC5846187
Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM,
Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human
Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017
Sep;23:52–58. PMID: 28803740. PMCID: PMC5605299
Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E,
Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir
plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000
copies/mL. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Dec 14; PMID: 29253097. PMCID: PMC5961075.
Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, Deleage C, Magyar C,
Nelson SD, Klingman KL, Bastow B, Luque AE, McComsey GA, Douek DC, Currier JS, Lake JE,
A5317 team. Telmisartan Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than
Continued ART Alone. J Infect Dis. 2018 Feb 1; PMID: 29401318. PMC5946950.
Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in
Previously Immunized HIV-Infected Children and Youth. J Pediatr Infect Dis Soc. 2017 Sep
1;6(3):e69–e74. PMID: 28339668. PMCID: PMC5907864.
Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD,
Dellon ES, De Paris K, Nelson JAE, Gay CL, Kashuba ADM. Virologic and Immunologic
Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIVInfected
Men and Women. Antivir Ther. 2018;in press.
Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD,
Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC
inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017 Aug 1;127(8):3126–3135.
PMID: 28714868. PMCID: PMC5531421
Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, Jacobson DL, Van Dyke RB,
Geffner ME, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
P219/219C Study, and the Pediatric HIV/AIDS Cohort Study (PHACS). Delay in sexual
maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS Lond Engl. 2017
Jun 1;31(9):1333–1341. PMID: 28358737. PMCID: PMC5472204
Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847
Cheng L, Yu H, Li G, Li F, Ma J, Li J, Chi L, Zhang L, Su L. Type I interferons suppress viral
replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI
Insight. 2017 Jun 15;2(12). PMID: 28614789. PMCID: PMC5470878
Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M,
Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K. Increasing JAK/STAT Signaling Function
of Infant CD4(+) T Cells during the First Year of Life. Front Pediatr. 2017;5:15. PMID: 28271056.
PMCID: PMC5318443
Gallo MF, Legardy-Williams J, Steiner MJ, Macaluso M, Carter M, Hobbs MM, Hylton-Kong T,
Anderson C, Costenbader E, Warner L. Sexual Relationship Power and Semen Exposure
Among Female Patients at a Sexually Transmitted Infection Clinic in Kingston, Jamaica. Arch
Sex Behav. 2017 Oct;46(7):2157–2164. PMID: 27305908. PMCID: PMC5500443
Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM,
Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, AIDS Clinical Trials
5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected
Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–1733.
PMID: 28431010. PMCID: PMC5790148
Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ,
Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody
Response Associates with Enhanced Transmission and Infant Morbidity. mBio. 2017 Oct
24;8(5). PMID: 29066544. PMCID: PMC5654929
Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, Kaunda-
Khangamwa B, Compliment K, Stanley C, Cataldo F, van Lettow M, Rosenberg NE, Tweya H,
Gugsa S, Sampathkumar V, Schouten E, Eliya M, Chimbwandira F, Chiwaula L, Kapito-Tembo
A, Phiri S, PURE Malawi Consortium. Viral Suppression and HIV Drug Resistance at 6 Months
Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. J Acquir
Immune Defic Syndr 1999. 2017 Jun 1;75 Suppl 2:S149–S155. PMID: 28498184. PMCID:
PMC5431274
Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez
AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm
Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected
Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT
P1025 Protocol. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Sep 15;65(6):982–989. PMID:
28575201.PMCID: PMC5849107
Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM,
Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human
Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017
Sep;23:52–58. PMID: 28803740. PMCID: PMC5605299
Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E,
Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir
plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000
copies/mL. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Dec 14; PMID: 29253097
Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in
Previously Immunized HIV-Infected Children and Youth. J Pediatr Infect Dis Soc. 2017 Sep
1;6(3):e69–e74. PMID: 28339668